According to a new study, the use of aspirin thrice or more times per week is linked to a decline in all-cause, any cancer, CRC (colorectal cancer), and gastrointestinal cancer deaths among older adults. Holli A. Loomans-Kropp from the NCI (National Cancer Institute), Maryland, along with colleagues analyzed the connection of aspirin use with all-cause, any cancer, CRC, and gastrointestinal mortality amongst 146,152 people (average age: 66.3 Years) who were monitored for a median of 12.5 Years. The study was published in the journal JAMA Network Open.
The researchers discovered that aspirin use once to thrice per month was associated with a reduced peril for all-cause and cancer deaths in comparison with no use (hazard ratio: 0.84 and 0.87, respectively). The decreased perils for mortality of all causes, any cancer, CRC, and gastrointestinal cancer were seen with aspirin use thrice or more times a week (hazard ratios, 0.81, 0.85, 0.71, and 0.75, respectively). On classification by BMI (body mass index), aspirin use thrice or more times every week associated with a decreased peril for all-cause and any cancer deaths amongst those having a BMI of 20–24 kg/m² (hazard ratio: 0.82 and 0.86, correspondingly) and with decreased peril for all-cause, any cancer, CRC, and gastrointestinal cancer death with a BMI of 25–29.9 kg/m² (hazard ratio: 0.82, 0.86, 0.66, and 0.72, respectively). The authors stated, “Future studies should further analyze the connection of BMI with the efficiency of aspirin as a cancer-protective agent to acclimatize to the changing obesity trends globally.”
On a related note, recently a study showed that low-dose aspirin does not reduce mortality from prostate cancer. The study was published in the Annals of Internal Medicine. Charlotte Skriver, from the DCRC (Danish Cancer Society Research Center), Copenhagen, and colleagues utilized a countrywide data registry to evaluate the link amid postdiagnosis use of low-dose aspirin and prostate cancer mortality. Researchers observed a link between postdiagnosis low-dose aspirin use and prostate cancer-specific deaths & other-cause mortality. The prostate cancer deaths were slightly decreased with postdiagnosis exposure to low-dose aspirin stages of 5 Years and 7.5 Years.